pirarubicin and Carcinoma--Papillary

pirarubicin has been researched along with Carcinoma--Papillary* in 2 studies

Trials

1 trial(s) available for pirarubicin and Carcinoma--Papillary

ArticleYear
Intravesical instillation of adriamycin for bladder tumors.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30 Suppl

    In the present series of trials, Adriamycin (ADM) intravesical instillation therapy was found to be effective against tumors of papillary morphology measuring less than 10 mm in diameter that were of low pathological stage and low histological grade. The rate of complete disappearance increased in proportion to the concentration of ADM and the duration of retention of the drug, although the efficacy rates were almost the same in each trial. On the other hand, side effects on the bladder were reduced when the instilled solution was lower in concentration and the retention time was short.

    Topics: Administration, Intravesical; Carcinoma, Papillary; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Time Factors; Urinary Bladder Neoplasms

1992

Other Studies

1 other study(ies) available for pirarubicin and Carcinoma--Papillary

ArticleYear
The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
    International journal of clinical oncology, 2006, Volume: 11, Issue:4

    Thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor, has been implicated in the angiogenesis of bladder cancer. The aim of this study is to investigate the association between TP expression and the clinicopathologic findings, and the prognostic value.. TP immunohistochemical staining was performed in specimens from 71 patients (50 men and 21 women) with superficial bladder cancer (pTa or pT1). Thirty-nine patients had received intravesical instillation of tetrahydropyranyladriamycin (THP) after transurethral resection (TUR) and the other 32 had not. For immunohistochemistry, paraffin-embedded specimens were stained with mouse monoclonal antibody against TP. When more than 10% of tumor cells were positively stained, staining was defined as positive. The correlations between TP immunostaining and clinicopathological features were analyzed. Multivariate analysis, using the Cox proportional hazard model, was performed to determine the risk factors for intravesical recurrence.. Specimens from 29 of the 71 patients (19 men and 10 women) were positive for TP. The expression of TP was not correlated with age, sex, histological grade, multiplicity, or morphology. Also, TP expression was not associated with whether the cases were primary or recurrent. Multivariate analysis demonstrated that the decreased expression of TP and the use of THP instillation could be independent predictors of a higher rate of intravesical recurrence-free bladder cancer.. The present study suggests that immunohistochemical TP staining is useful for predicting the intravesical recurrence of superficial bladder cancer after Transurethral resection of bladder tumor (TUR-Bt).

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Papillary; Carcinoma, Transitional Cell; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Preventive Medicine; Prognosis; Proportional Hazards Models; Regression Analysis; Thymidine Phosphorylase; Urinary Bladder Neoplasms

2006